New hope for advanced prostate cancer: HRS-4357 takes on standard drugs in major trial
NCT ID NCT07311694
First seen Jan 07, 2026 · Last updated Jun 11, 2026 · Updated 26 times
Summary
This study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will enroll 370 men and measure how long the cancer stays under control. The goal is to see if HRS-4357 works better at delaying cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201321, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.